Comparative Table: GLYCERYL TRINITRATE INJECTION*

Brand	GLYCERYL TRINITRATE WOCKHARDT	DBL GLYCERYL TRINITRATE, HOSPIRA GLYCERYL TRINITRATE
Container Type and Volume	**50mL glass vial**	10mL glass ampoule
Content GTN	**50mg (1mg per mL)**	50mg (5mg per mL)
Preservative Free	**Yes**	Yes
Route of Administration	**i.v.**	i.v.
Ethanol Content	**Ethanol free**	6.69mL Absolute Ethanol per 10mL (66.9%)
Other Excipients	**Glucose**	Propylene Glycol
	Glucose monohydrate	Water for Injections
	Propylene Glycol	
	Water for Injections	
Adverse Effects (differences)		Alcohol intoxication has been reported in patients receiving high dose intravenous infusions.

*as per TGA Approved Product Information at the time of publication (May 2019)

WOCKHARDT

Distributed in Australia by: Wockhardt Bio Pty Ltd c/o InterPharma Pty Ltd
Suite 103 / 39 East Esplanade, Manly NSW 2095 Ph: 02 9976 6876
www.interpharma.com.au

Pharmaovigilance and Medical Information: +61 2 9846 1950

Before prescribing, please review full Product Information (PI) available on request from InterPharma.

GLYCERYL TRINITRATE WOCKHARDT (Glyceryl trinitrate 50mg/50mL) CONCENTRATED solution for Injection
Minimum Product Information: Indications: Blood pressure control in perioperative hypertension; congestive heart failure due to acute myocardial infarction; angina pectoris in patients non-responsive to organic nitrates/beta blocker; controlled hypertension in neurosurgical/orthopaedic surgery procedures. **Contraindications:** Hypersensitivity to glyceryl trinitrate/organic nitrates or excipients; hypotension/uncorrected hypovolemia; increased intracranial pressure; constrictive pericarditis and pericardial tamponade; severe anaemia or arterial hypoxaemia; coadministration of sildenafil and soluble guanylate cyclase stimulator; obstructive cardiomyopathy (especially with aortic or mitral stenosis/constrictive pericarditis). **Precautions:** Not for intravenous injection; dilute in 5% glucose OR 0.9% sodium chloride pre-infusion; administration set used affects active amount delivered; only use in acute myocardial infarction for treating definite left ventricular failure; careful dose titration required to avoid precipitous blood pressure decrease; avoid excess hypotension and for prolonged periods; vasodilators use in hypertensive patients suspected of causing acute blindness; tolerance/cross tolerance may occur with long term/repeated use of organic nitrates; nitrate dependence; caution in patients with severe ischaemic heart disease/pulmonary disease due to hypoxaemia; methaemoglobinaemia; patients with malnutrition, hypothermia, hypothyroidism, hyperthyroidism, severe hepatic/renal disease, elderly patients; not recommended in children; contains glucose; may affect certain laboratory tests (refer PI for details). **Interactions:** Alcohol, levodopa, pancuronium, morphine, ergot alkaloids, tricyclic antidepressants, anticholinergics, vasodilators, antihypertensives, major tranquillisers, opioids; aspirin, non-steroidal anti-inflammatory drugs, noradrenaline, sympathomimetics, heparin. **Pregnancy Category B2;** Caution with lactation. **Adverse Events:** Generally dose related; headache, tachycardia, nausea, vomiting, apprehension, restlessness, muscle twitching, retrosternal discomfort, palpitations, dizziness and abdominal pain; hypotension, bradycardia; hyperosmolarity due to propylene glycol solvent. **Dosage:** Initially 5µg/min (for non-absorbing tubing) then titrated at 5µg/min increments every 3-5 mins according to clinical situation and until response noted. If no response at 20µg/min, use 10µg/min then 20µg/min increments. Once partial response observed, reduce dose increase and lengthen dosage increment interval. No fixed optimum dose; continuous monitoring of physiologic parameters required. **Administration:** Initial dilution in 450mL of 5% glucose or 0.9% sodium chloride for final concentration of 100 µg/mL.
Refer PI for maintenance dilution instructions. Based on Product Information dated 7 May 2019.

WOCKHARDT

Distributed in Australia by: Wockhardt Bio Pty Ltd c/o InterPharma Pty Ltd
Suite 103 / 39 East Esplanade, Manly NSW 2095 Ph: 02 9976 6876
www.interpharma.com.au

Pharmaovigilance and Medical Information: +61 2 9846 1950